Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05614947 · ClinicalTrials.gov registry record · NA

Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome

A NA study of Metabolic Syndrome, sponsored by Ohio University.

Completed
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT05614947 is a NA study of Metabolic Syndrome that has completed, run by Ohio University. The registered enrollment target is 25 participants, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05614947, a NA study of Metabolic Syndrome, has completed, sponsored by Ohio University.

COMPLETED
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease target. The primary treatment for MetSyn is exercise and weight loss, along with medically necessary treatment. Exercise, along with dietary changes such as increased fiber and polyphenol intake can positively impact many of the metabolic abnormalities seen with MetSyn. For example, polyphenols have been shown to decrease lipid concentration and improved glucose clearance as well as decreased oxidative stress and inflammation. Powdered tart cherry capsules, which contain the skin of the fruit, provides polysaccharides (fiber) that would likely act as a substrate for gut bacteria degradation, providing energy substrates and barrier integrity to the colonocytes and increasing the bioavailability of the polyphenols to other cells in the body. However there have been no long-term investigations into the use of powdered tart cherry supplements in MetSyn, therefore we aim to determine if 60 days tart cherry supplementation modify criteria for MetSyn in currently diagnosed individuals including body mass, waist circumference, blood pressure, blood lipid levels and blood glucose control.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Powdered tart cherry

Study Locations (1)

Ohio

  • Ohio University Exercise Physiology Lab - Athens

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2022-04-06
Est. Completion 2025-07-25
Phase NA

Sponsor

Ohio University

51 total trials

What the Registry Record Tells You About NCT05614947

The ClinicalTrials.gov registry entry for NCT05614947 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,205-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (98% lower). The listed sponsor is Ohio University, which has 51 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metabolic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05614947 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05614947 about?

NCT05614947 is a clinical study titled "Impact of 60 Days Powdered Tart Cherry Supplementation on Metabolic Syndrome". Metabolic syndrome (MetSyn) is a growing health concern, with up to 25% of the worlds population having the syndrome. MetSyn is a primary risk factor for cardiovascular disease and type II diabetes development, and is independently associated with all-cause mortality, making it an important disease ...

What is the current status of trial NCT05614947?

This trial is currently completed. It is a NA study. The enrollment target is 25 participants. The study started on 2022-04-06. Estimated completion is 2025-07-25.

What conditions does trial NCT05614947 study?

This clinical trial studies the following conditions: Metabolic Syndrome.

What interventions are being tested in trial NCT05614947?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Powdered tart cherry (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05614947?

This trial is sponsored by Ohio University, which has 51 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05614947 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.